Aim. The aim of our retrospective study was to answer the question if the presence of cardiovascular autonomic neuropathy (CAN) affects mortality in type 1 diabetic patients during a 10-year follow-up. Methods. Patients with type 1 diabetes mellitus examined for CAN in 2003 were enrolled in this retrospective study. A total of 278 patients were included and divided into two groups according to the presence or absence of CAN (111 CAN+, 167 CAN-). The group characteristics and outcomes were compared at baseline and after ten years (in 2013). Results. In the follow-up period, a total of 18 patients died; CAN+ (14/111; 12.6%) and CAN-(4/167; 2.4%) (P < 0.001). At baseline, the CAN+ patients were older (47 vs. 33 years; P < 0.001), had longer duration of diabetes (20 vs. 12 years; P < 0.05), had worse glycemic control assessed by HbA1c (73 vs. 68 mmol/mol; P < 0.05), higher systolic (130 vs. 120 mmHg; P < 0.001) and diastolic (80 vs. 70 mmHg; P < 0.01) blood pressure and had more diabetic complications. In our analysis we found the strongest predictor of mortality to be the presence of CAN (P < 0.01) and the blood pressure value at baseline (P < 0.05). Other baseline characteristics, including the duration of diabetes, age and the presence of micro-and macrovascular complications were not significant. The statistical analysis was performed using logistic regression step-wise analysis. Conclusions. During the 10-year follow-up, CAN+ patients had a 5-fold higher mortality rate than CAN-patients. The strongest predictor of mortality was the presence of CAN.
INTRODUCTION
For a long time now, CAN has not been considered the Cinderella of diabetes complications 1 . Every year, numerous articles addressing this chronic complication come out; 99% of them stating that CAN significantly increases the morbidity and mortality of affected patients. This conclusion is based on pathophysiology, nevertheless, no clinician is comfortable with accepting the fact that 29% patients with CAN die within 10 years 2 compared to 6% of patients without CAN. Our doubts regarding this information led us to organize this study. The outpatient clinic of the Diabetes Center in the University Hospital in Pilsen, Czech Republic follows about 600 patients with type 1 diabetes mellitus (DM1). Since 1998, examination of CAN is included in the regular screening for microvascular complications. The aim of this study was to compare the DM1 patients with and without CAN to answer the question if the presence of CAN affects the mortality of type 1 diabetic patients during a 10-year follow-up.
METHODS
Patients with DM1 examined for CAN in 2003 were enrolled in a retrospective study. The inclusion criteria were DM1 duration of more than one year before the examination for CAN, the absence of severe diabetes complications at the time of CAN examination (defined as the presence of end-stage renal disease (ESRD), history of major leg amputation, blindness), the absence of other severe diseases (malignancy, heart failure NYHA III-IV, alcoholism) and age between 18-70 years. In total, 278 patients were enrolled and divided into two groups according to the presence or absence of CAN (111 CAN+, 167 CAN-). The groups were compared at baseline and after ten years in 2013. The assessment of CAN was performed under strictly standardized conditions by a bedside on-line telemetric transmitter (VarCor PF7, DIMEA Group, Olomouc, Czech Republic). International recommendations were used for evaluation of the results 3, 4 . Three tests from the Ewing battery were selected for CAN assessment: (i) Heart rate variability in response to deep breathing (parameter I/E), (ii) Laying-to-standing heart rate response (parameter RRmax/RRmin), (iii) Postural blood pressure change. The values of each patient were approximated to age according to international guidelines [5] [6] [7] .
Patients having positive ≥ 2 of the 3 tests were enrolled in the CAN+ group and patients having positive ≤ 1 test were included in the CAN-group.
The following variables were compared at baseline and after 10 years (median 9.72 years): glycemic control (HbA1c; mmol/mol), weight (kg), blood pressure (mean of two subsequent measured values; mmHg), estimated Glomerular Filtration Rate (eGFR; mL/s) calculated as Modification of Diet in Renal Disease (MDRD). Albumin excretion rate from the collection of night urine (AER; ug/min; without AER < 20 ug/min; with AER > 20 ug/ min), retinopathy (ophthalmoscopy) and peripheral neuropathy (monofilaments; biothesiometer and Neuropad) were evaluated as present (1) or absent (0). Positivity of at least two out of three performed neuropathy tests was necessary for the diagnosis of neuropathy 8 . Diabetic foot (DF) was defined as a soft tissue ulceration or a bone affection under the level of the ankle associated with neuropathy and/or ischemia and/or amputation. The presence of cardiovascular disease was defined as the presence of one or more of the following: myocardial infarction, angina pectoris, a history of angioplasty or coronary bypass, transient ischemic attack, cerebrovascular event or the presence of peripheral vascular disease. The follow-up included the assessment of the presence of arterial hypertension on treatment, hyperlipoproteinemia and smoking.
The number of deaths and the cause of death were assessed. The data was obtained from the Diabetes Center of the University Hospital in Pilsen registry and from the Department of Forensic Medicine of the Medical Faculty in Pilsen, Charles University in Prague.
Data were tested for normality and parametric and non-parametric comparisons were used as appropriate. Median and interquartile range were used for descriptive analysis. Median differences between baseline and 10-year follow-up were compared using Wilcoxon unpaired test, categorical variables were analyzed with Chi-square test (χ 2 ). Stepwise logistic regression analysis was used for the assessment of the risk factors for mortality.
RESULTS
Severe CAN was diagnosed in 111 (39.9%) of the enrolled 278 DM1 patients that were examined for the presence of CAN in 2002-2004 and fulfilled the inclusion criteria. The baseline characteristics and group comparison are shown in Table 1 and 2.
At baseline, the patients in CAN+ were older (47 vs. 33 years; P < 0.001), had longer duration of diabetes (20 vs. 12 years; P < 0.05), worse glycemic control (HbA1c) (73 vs. 68 mmol/mol; P < 0.05), higher systolic (130 vs. 120 mmHg; P < 0.001) and diastolic (80 vs. 70 mmHg; P < 0.01) blood pressure and lower eGFR (1.16 vs. 1.35 mL/s; P < 0.001). The presence of retinopathy (67.6 vs. 21.6 %; P < 0.001), peripheral neuropathy (59.5 vs. 18.6 %; P < 0.001), DF (6.3 vs. 0 %; P < 0.01) and AER (41.4 vs. 11.4 %; P < 0.001) was also more frequent in the CAN+ group at baseline. Higher presence of CVD (6.3 vs. 0.6%; P < 0.01), hypertension on treatment (32.4 vs. 6.6%; P < 0.001) and hyperlipoproteinemia (29.7 vs. 16.8 %; P < 0.05) in the CAN+ group was also observed. The proportion of smokers (19 vs. 21.6 %) was similar in both groups.
In the follow-up period, a total of 18 patients died (18/278; 6.5%); 14 from the CAN+ group (14/111; 12.6%) and 4 from the CAN-group (4/167; 2.4%) (P < 0.001) ( Table 3 ). The main predictors of mortality were the presence of CAN (P < 0.01) and systolic blood pressure at baseline (P < 0.05). Duration of diabetes at baseline, age and the presence of micro-and macrovascular complications were not significantly associated with the mortality rate ( Table 4) .
Analysis of the cause of death showed that 8 patients died of diabetes complications, 3 patients of CVD and 7 patients died of other causes (Table 5) .
DISCUSSION
The prevalence of CAN in our group of patients was 39.9% (111/278). This number is comparable with our previous results 9 , as well as with the results published by other authors. The prevalence of CAN is usually reported to be between 20 and 65% (ref. 10 ). However, there is wide variability, from 2.5%, in patients with short duration of diabetes 11 up to 90% in patients waiting for pancreas transplant 12 . CAN is often asymptomatic for a long time, as seen in our study, and it is rarely included in the screening of chronic complications. This can explain the differences in the prevalence observed amongst the studies. In addition, the rate of CAN diagnoses depends on the type and number of cardiovascular tests used (e.g. Ewing battery, Spectral analysis of heart rate variability). To date, there is no consensus regarding the optimal screening for CAN. If the evaluated group is large, even one test can be sufficient to diagnose CAN, as seen in the EURODIAB study 13 . In a consensus published in 2011 by a working group lead by Spallone, at least two abnormal cardio-vagal tests and the presence of orthostatic hypotension are recommended for the identification of severe or advanced CAN (ref. 10 ). In our study, the selection of the tests was the same (I/E, RRmax/RRmin, orthostatic hypotension test). According to May and Arildsen, each test from the Ewing battery holds a significant predictive value for the assessment of mortality 14 . In agreement with the studies referenced below, we showed that the patients in the CAN+ were older and had a longer duration of diabetes. The factor of time in the relation to the presence of CAN is logical. The reactivity of the autonomic nervous system naturally decreases with age, therefore the results of individual tests must be approximated to age [5] [6] [7] . There are only a few studies demonstrating the presence of CAN early after the manifestation of DM (ref. 15 ). Poor diabetes control itself is considered to be an another risk factor for the development of CAN, especially in DM1 (ref. 10 ). There is no doubt that hyperglycemia drives the pathophysiological processes leading to virtually all chronic complications of diabetes. Also for CAN, the effect of good 11 and especially early glycemic control has been demonstrated. In the DCCT study, the conventionally treated group showed an increase in CAN as high as 35%, compared to the intensively-treated group 16 . The effect of good glycemic control on the sympathetic innervation of the myocardium was demonstrated by Ziegler in his 4-year prospective study. Using metaiodobenzylguanidine scintigraphy, he was able to prove that the autonomic innervation was worse in the Table 3 . Mortality in group CAN+ and CAN-during 10 years follow up.
Results are given as number of cases (%) CAN+/ CAN-, the group with/without cardiovascular autonomic neuropathy; χ2, Chi-square test. 17 . Even stronger evidence of positive effect of normoglycaemia is provided in a recently published study 18. Our group of CAN+ patients had a higher overall presence of microvascular complications at baseline. The mutual relationship of CAN and these complications has been assessed in a number of studies [19] [20] . In our previous study, we were able to demonstrate that the presence of CAN can be predicted based on the mutual relationship with other chronic complications. A patient with concurrent peripheral neuropathy, hypertension and microalbuminuria has as well a high probability of having CAN 9 . In our study, these complications were present concomitantly as well. Peripheral neuropathy was present in 59.5% of patients with CAN and only in 18.6% of patients without CAN (Table 2) . CVD, hypertension on treatment and hyperlipoproteinemia were too found more frequently in the CAN+ group already at baseline. These risks, however, are more commonly found in patients with type 2 diabetes mellitus 10 . In one issue of EURODIAB Prospective Complications Study, Witte suggested that the risk factors of CAN could be of equal importance as the classical cardiovascular risk factors 21 . Similar results were presented in another EURODIAB study led by Kempler et al. 13 . In a group of 3007 DM1 patients, he was able to demonstrate that the presence of CAN was associated with age, diabetes duration, glycemic control, blood pressure, lower level of HDL cholesterol, total cholesterol/HDL cholesterol ratio, triglycerides, the presence of retinopathy and albuminuria, and smoking. In our study however, the number of smokers in both groups was similar. In spite of the decreasing overall mortality rate of DM1 patients and the markedly extending period from diabetes onset to death, the prognosis of the patients with DM1 is still worse than in the non-diabetic population. A recently published study suggests a strong relationship between poor glycemic control and excess of both total and cardiovascular mortality in patients with DM1 (ref. 22 ).
A British study has shown the annual mortality in DM1 patients to be 8/1000, whereas in the non-diabetic population only 2.4/1000. The increased mortality in DM1 patients has been observed in all age groups. In gender analysis, the difference turned out to be even more pronounced in women 23 . The number of deaths and the cause of death in DM1 patients may be additionally influenced by the factor of time -most importantly by the duration of diabetes and the calendar year of diabetes onset 24 . A Japanese study assessing the causes of death in childhood-onset DM1 patients found that CVDs were the main causes of the death of patients with duration of diabetes longer than 20 years. Therefore is necessary to start monitoring the cardiovascular risk factors early 25 , as the age of onset (before/after puberty) may be a risk factor for the development of complications. An Italian study confirmed that the mortality of DM1 patients is twice as high as the general Italian population of the same age, and those with DM onset after puberty are at higher risk of mortality 26 . Characterizing the whole group of patients followed in our study, the median age at baseline (years 2002-2004) was 37.5 years, with the mean diabetes duration of 15 years (onset in 1989) and manifestation after puberty in 22.5 years ( Table 1) . The overall group mortality rate was 6.5/1000/year.
If we assess the mortality rate in relation to the presence or absence of CAN, we can look at the most cited works in this area, Ziegler et al. 2 and Rathmann et al. 27 and conclude that there is an increased mortality of patients with CAN. Ziegler et al. performed a meta-analysis of 9 studies showing that 29% of diabetics with CAN compared to 6% of diabetics without CAN die within 10 years (Table 6 ). However, only one study followed the patients for 10 years, with two other studies having an 8 year follow-up, four studies having only 5 years of followup data, and in Ewing's study following the patients for only 3 years (mean length of follow-up of all studies 5.8 years). All the studies differed in the number and type of the Ewing battery tests used (in four studies, only 1-2 tests were used and one study used all five tests, with three studies adding the QTc parameter to the testing battery). Overall, in all 9 studies there were 495 patients with CAN and 708 patients without CAN and 29% of patients with CAN (143) compared with 6% (41) without CAN died. In two studies the difference in mortality between the two studied groups was statistically insignificant, in seven it reached statistical significance. Not all patients had DM1. Only two studies followed a larger group of patients (232 and 506), however the follow-up time was relatively short, only 3.3 and 5 years, respectively 28, 29 . The remaining seven studies had small sample sizes, ranging from 53 to 87 patients. One of the 9 studies mentioned is that of Rathmann et al. 27 , where at the beginning of this study, more than 1000 patients were examined and only 35 patients with CAN and 35 without CAN were selected for the 8-year follow-up. Within the eight years, 23% (8) of patients from the CAN group compared to 3% (1) without CAN died. This study included both DM1 and DM2 patients.
In our study groups, only DM1 patients were included, the length of follow-up was 10 years (mean 9.72) and three tests were used for diagnostics of CAN. The presence of CAN and the systolic blood pressure value at baseline were identified as the strongest predictors of mortality. The glycemic control at baseline was approaching significance. Baseline diabetes duration, age as well as other variables (the presence of micro-and macrovascular complications) were not significant (in a logistic regression, step-wise analysis). In our study, the percentage of patient death was about a half in both groups (12.4% vs. 2.4%) compared to Ziegler's meta-analysis (29% vs. 6%), but the relative difference in mortality between the group with and without CAN was comparable. In our study, 5.3 times more patients from the CAN+ group died compared to CAN-group. In Ziegler's meta-analysis, the difference in mortality was 4.8-fold. The greater number of deceased patients in Ziegler's meta-analysis could be explained by the design of the individual studies, where older patients with type 2 diabetes were also enrolled. Furthermore, the fact that the studies included in the meta-analysis were performed more than 20 years ago could play an important role. General care of a patient with diabetes mellitus and CVD has changed dramatically over the 20 years. The presence of CAN was classified as a strong predictor of mortality even by the EURODIAB study authors. Microvascular complications, such as macroalbuminuria and peripheral and autonomic neuropathy, were considered strong markers of future mortality risk and exceed the traditional cardiovascular risk factors in their importance 30 . The negative effect of CAN on inpatient and long-term mortality after a myocardial infarction was confirmed in a study from Montenegro. Patients with DM and CAN had worse results in all observed variables than DM patients without CAN, while the results of DM patients were generally worse than of non-DM patients 31 . It is difficult to prove that CAN responsible for a death. Malignant arrhythmia is mentioned most frequently, especially if elongation of the QTc interval was documented. A myocardial contractility disorder leading to diastolic dysfunction has other causes. A further possibility is a central respiratory disorder and "dead in bed syndrome" attributed to malignant arrhythmia induced by increased sympathetic nervous system tone during hypoglycemia 32 . The causes of death in our group are presented as individual cases in Table 5 . Even though diabetic nephropathy in the ESRD stage is not anymore the leading cause of death, nephropathy is a factor that potentiates the very cardiovascular mortality of this group up to tenfold 33 . Most studies conclude that if DM1 patients die within 10 years of diabetes duration, the death is usually caused by acute complications (hypoglycemia, diabetic ketoacidosis). If the DM1 duration is about 20 years, ESRD has a share, and in diabetes lasting for longer than 20 years, the leading cause of death is CVD. Even in our small study, the causes of death follow a similar pattern 34 .
Study limitations and strengths
The strength of the study is the duration of follow-up of a large group of DM1 patients. The depth of source data collection, including information regarding death are also advantages. The main limitations may be the retrospective design and the fact that it is a single-center study. Use of modified tests of heart rate variability spectral analysis 35 might contribute to facilitation and spread of CAN assessment.
CONCLUSIONS
Despite the original objective of the study to rebut the pessimistic prediction of CAN prognosis, our retrospective study confirmed the seriousness of CAN. Over the 10-year follow-up, the mortality rate was 5 times higher in the group of DM 1 patients with CAN compared to patients without CAN. Although there were already baseline differences between CAN+ and CAN-patients in age and morbidity, the presence of CAN was statistically the strongest predictor of mortality.
